Impilo invests in Lowenco – a pioneer in ultra-low temperature storage solutions
VAMDRUP, Denmark, February 3rd, 2022 – Impilo, together with SHS, have acquired Lowenco A/S (“Lowenco” or the “Company”) from its founder and owners.
Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance market. Following an initial period of product refinement and establishment of go-to-market activities, Lowenco has over the past three years gained significant commercial traction and is today a preferred supplier of sustainable large scale modular ULT storage solutions to several of the largest biotech and pharmaceuticals companies across the globe.
The Company is well positioned to continue addressing the increasing demand for large scale ULT storage solutions, underpinned by the strong underlying growth in biopharma volumes, leveraging its unique customer value proposition that is centred around superior quality, performance and service, leading energy efficiency, and significantly lower cost of ownership. Following the transaction, Lowenco’s management team will remain intact, led by CEO Mikael Hoier, who has been part of the management team since 2017.
Magnus Edlund, Partner at Impilo, the new majority owner, and Manfred Ulmer-Weber, Partner at SHS, comment: “Lowenco provides a disruptive value proposition to an underserved and attractive niche market with strong structural tailwinds, where sustainable and premium quality solutions are rightfully gaining increased attention. As biopharma volumes continue to grow, Lowenco will be perfectly positioned to meet these growing demands and will continue its close cooperation with biopharma customers and CDMOs around the world to improve the quality and sustainability of ULT storage. Impilo and SHS are excited about working together with the management team to further expand and penetrate the Company’s customer base and strengthen its position globally”.
Mikael Hoier, CEO of Lowenco, comments: “We believe Impilo’s and SHS’ combined experience in healthcare makes them ideal partners to take Lowenco to the next level of success, and we look forward to continuing to work closely together to remain in the forefront of delivering innovative ULT storage solutions to our growing customer base. By partnering with Impilo and SHS we will be able to develop the Company even faster to the benefit of our existing and new customers. The entire Lowenco team are very much looking forward to this next exciting chapter in the development of Lowenco”.
In connection with the transaction, Michael Berg, former CEO of Envirotainer, will be appointed Chairman of the Board of Lowenco.
“Lowenco’s novel large scale modular product approach allows for outstanding space- and energy efficiency coupled with superior technical performance, resulting in by far the best sustainability and lifetime cost profile on the market. This disruptive technology will pave the way for an exciting future in the structurally growing and non-cyclical biopharmaceuticals markets. I look forward to contributing to the Company’s development”, says Michael Berg.
For further information, please contact:
Magnus Edlund, Partner at Impilo, +46761151061, firstname.lastname@example.org
Manfred Ulmer-Weber, Partner at SHS Capital, +4970719169150, email@example.com
Mikael Hoier, CEO of Lowenco, +4525808010, firstname.lastname@example.org
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. The Company strives to increase value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of investments and manages c. EUR 1 billion of capital from leading Nordic and international investors. The acquisition of Lowenco marks Impilo’s fourth investment in Denmark since its foundation in 2017, following the acquisitions of Ferrosan Medical Devices, Scantox, and tandl gen.dk. Learn more about Impilo at www.impilo.se.
"Building European Healthcare Champions" is the guiding principle of the Tübingen-based sector investor SHS. Since its foundation in 1993, the focus of its investments has been on expansion financing, shareholder changes and succession situations. In doing so, SHS takes both minority and majority stakes. Investors in SHS funds include pension funds, funds of funds, family offices, entrepreneurs, strategic investors and the SHS management team. The equity investment of the AIFM-registered company is up to EUR 20 million. Volumes exceeding this can be realised with a network of co-investors. SHS is currently investing from its fifth fund, which was launched in 2018. Learn more at www.shs-capital.eu.
Founded in 2013 and headquartered in Vamdrup, Denmark, Lowenco is a leading manufacturer of ultra-low temperature (“ULT”) storage solutions for the pharma and biotech industries. The Company serves a growing global customer base and its unique highly energy efficient and sustainable ULT storage solutions, developed under the brand names LSSU and CON20, offer superior quality and technical performance, as well as lower cost of ownership. Lowenco follows GMP guidelines and has a steadily increasing R&D pipeline. Learn more at www.lowenco.com.